ARTICLE | Clinical News
ALLN-177: Phase IIa data
March 23, 2015 7:00 AM UTC
An open-label, U.S. Phase IIa trial in 16 patients with recurring kidney stones and enteric or idiopathic hyperoxaluria showed that oral ALLN-177 given up to 3 times daily with meals for 4 days led to...